Antifungal management.
University of Florida Shands Cancer Center, Gainesville, FL, USA.
John
J
Wingard
D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D036101:Cord Blood Stem Cell Transplantation; D054714:Echinocandins / Q000627:therapeutic use; D006801:Humans; D007938:Leukemia / Q000628:therapy; D008168:Lung / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000473:pathology; D011183:Postoperative Complications / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D055732:Pulmonary Aspergillosis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D011743:Pyrimidines / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use; D065819:Voriconazole
D000935:Antifungal Agents; D054714:Echinocandins; D011743:Pyrimidines; D014230:Triazoles; C068538:liposomal amphotericin B; D000666:Amphotericin B; D065819:Voriconazole